Physician profile
Robert Szeliga
NPI 1982778825
$44,267.39
in general payments reported to CMS, 2019-2025
21 companies · $4,097 in 2025
The $4,097 reported for 2025 was more than what 99% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,491 · 2020: $4,265 · 2021: $9,623 · 2022: $13K · 2023: $2,014 · 2024: $5,063 · 2025: $4,097.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,603 · Consulting Fee: $3,780 · Travel and Lodging: $2,792.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,602.66 |
| Consulting Fee | $3,780.00 |
| Travel and Lodging | $2,791.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $36,762.19 | 2019-2025 | Precision 7, Air Optix, Dailies Aqua Comfort Plus |
| Coopervision INC. | $4,819.62 | 2019-2025 | Biofinity Contact Lens, Myday Contact Lens, Misight Contact Lens |
| Lumenis Be INC | $973.55 | 2025 | Optilight |
| Johnson & Johnson Vision Care, INC. | $356.50 | 2019-2025 | Acuvue |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $275.92 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $228.00 | 2022-2025 | Infuse, Scoutpro Osmolarity System, Vyzulta |
| Novartis Pharmaceuticals Corporation | $158.26 | 2019-2020 | |
| Biotissue Holdings INC. | $147.82 | 2021-2025 | |
| Abbvie INC. | $143.39 | 2022-2025 | |
| Dompe US, INC. | $79.93 | 2024-2025 | Oxervate |
| Allergan, INC. | $60.73 | 2021-2022 | |
| Maculogix, INC. | $53.03 | 2019 | |
| Abb Con-Cise Optical Group LLC | $44.47 | 2020 | |
| Kala Pharmaceuticals, INC. | $34.96 | 2021 | |
| Shire North American Group INC | $23.90 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Carl Zeiss Meditec, INC. | $23.50 | 2019 | |
| Tearlab Corp | $20.11 | 2024 | Scoutpro Osmolarity System |
| Lombart Brothers, INC. | $17.77 | 2019 | |
| Oyster Point Pharma, INC. | $17.31 | 2022 | |
| Spark Therapeutics, INC. | $13.35 | 2022 | |
| Alcon Research LLC | $13.08 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Szeliga listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.